Mucosal cytokine imbalance in irritable bowel syndrome

References

• Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480–91
   PubMed Web of Science ®Google Scholar
• Leong SA, Barghout V, Birnbaum HG, Thibeault CE, Ben-Hamadi R, Frech F, et al. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003; 163: 929–35
   PubMed Web of Science ®Google Scholar
• Quigley EM, Bytzer P, Jones R, Mearin F. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liver Dis 2006; 38: 717–23
   PubMedGoogle Scholar
• Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome: a meta-analysis. Am J Gastroenterol 2006; 101: 1894–9
   PubMed Web of Science ®Google Scholar
• Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003; 124: 1662–71
   PubMed Web of Science ®Google Scholar
• Gwee K-A, Leong Y-L, Graham C, McKendrick MW, Collins SM, Walters SJ, et al. The role of psychological and biological factors in post-infective gut dysfunction. Gut 1999; 44: 400–6
   PubMed Web of Science ®Google Scholar
• Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804–11
   PubMed Web of Science ®Google Scholar
• Chadwick V, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778–83
   PubMed Web of Science ®Google Scholar
• Gwee K-A, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, et al. Increased rectal mucosal expression of interleukin 1 beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523–6
   PubMed Web of Science ®Google Scholar
• Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972–9
   PubMed Web of Science ®Google Scholar
• Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693–702
   PubMed Web of Science ®Google Scholar
• O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541–51
   PubMed Web of Science ®Google Scholar
• Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?. Gastroenterology 2006; 130: 304–11
   PubMed Web of Science ®Google Scholar
• Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913–20
   PubMed Web of Science ®Google Scholar
• Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117: 636–47
   PubMed Web of Science ®Google Scholar
• Holmen N, Isaksson S, Simren M, Sjovall H, Ohman L. CD4+CD25+ regulatory T cells in irritable bowel syndrome patients. Neurogastroenterol Motil 2007; 19: 119–25
   PubMed Web of Science ®Google Scholar
• Langhorst J, Wieder A, Rueffer A, Michalsen A, Musial F, Dobos GJ. Activated innate mucosal immune system in irritable bowel syndrome? Gut 2007; Epub ahead of print.
   Web of Science ®Google Scholar
• Quigley EM. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis 2007; 8: 2–7
   PubMed Web of Science ®Google Scholar
• Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994; 106: 533–9
   PubMed Web of Science ®Google Scholar
• Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?. Gut 2003; 52: 91–3
   PubMed Web of Science ®Google Scholar
• van der Veek PP, van den berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterology 2005;100:2510–6.
   PubMed Web of Science ®Google Scholar
• McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003; 52: 975–80
   PubMed Web of Science ®Google Scholar
• Whorwell PJ, Altinger L, Morel J, Bond Y, Charbonneau D, O'Mahony L, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 326–33
   PubMed Web of Science ®Google Scholar
• Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45 Suppl II:II43–7.
   PubMedGoogle Scholar
• Dallas PB, Gottardo NG, Firth MJ, Beesley AH, Hoffmann K, Terry PA, et al. Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR: how well do they correlate?. BMC Genomics 2005; 6: 59
   PubMed Web of Science ®Google Scholar
• Kagnoff MF, Eckmann L. Epithelial cells as sensors for microbial infection. J Clin Invest 1997; 100: 6–10
   PubMed Web of Science ®Google Scholar
• Lyman SD, Escobar S, Rousseau AM, Armstrong A, Fanslow WC. Identification of CD7 as a cognate of the human K12 (SECTM1) protein. J Biol Chem 2000; 275: 3431–7
   PubMed Web of Science ®Google Scholar
• Yang XP, Albrecht U, Zakowski V, Sobota RM, Haussinger D, Heinrich PC, et al. Dual function of interleukin-1beta for the regulation of interleukin-6-induced suppressor of cytokine signaling 3 expression. J Biol Chem 2004; 279: 45279–89
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651–9
   PubMed Web of Science ®Google Scholar
• Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203–9
   PubMed Web of Science ®Google Scholar
• Ohman L, Isaksson S, Lundgren A, Simren M, Sjovall H. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 980–6
   PubMed Web of Science ®Google Scholar
• Bradley HK, Wyatt GM, Bayliss CE, Hunter JO. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 1987; 23: 29–32
   PubMed Web of Science ®Google Scholar
• Si JM, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10: 1802–5
   PubMed Web of Science ®Google Scholar
• Malinen E, Rinttila T, Kajander K, Matto J, Kassinen A, Krogius L, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373–82
   PubMed Web of Science ®Google Scholar
• Matto J, Maunuksela L, Kajander K, Palva A, Korpela R, Kassinen A, et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome: a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005; 43: 213–22
   PubMed Web of Science ®Google Scholar
• Maukonen J, Satokari R, Matto J, Soderlund H, Mattila-Sandholm T, Saarela M. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 2006; 55: 625–33
   PubMed Web of Science ®Google Scholar
• Kassinen A, Krogius-Kurikka L, Mekivuokko H, Rinttile T, Paulin L, Corander J, , et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy controls. Gatroenterology 2007; Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Yang D, Chen O, Hoover DM, Staley P, Tucker KD, Lubkowski J, et al. Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol 2003; 74: 448–55
   PubMed Web of Science ®Google Scholar
• Arimochi H, Morita K, Kataoka K, Nakanishi S, Kuwahara T, Ohnishi Y. Suppressive effect of Clostridium perfringens-produced heat-stable substance(s) on proliferation of human colon adenocarcinoma HT29 cells in culture. Cancer Lett 2006; 241: 228–34
   PubMed Web of Science ®Google Scholar